Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients

References

• Bromet EJ, Fenning S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999;46:871–81.
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Welham J, EL Saadi O, Maccauley C, Chant D. A systematic review of the incidence of schizophrenia: The distribution rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2004;2:13, doi: 10.1186/1741 - 7015-2–13.
   PubMed Web of Science ®Google Scholar
• Schultz SH, North SW, Shields CG. Schizophrenia: A review. Am Fam Physician 2007;75:1821–9.
   PubMed Web of Science ®Google Scholar
• Perlick D, Stastny P, Mattis S, Teresi J. Contribution of family, cognitive and clinical dimensions to long-term outcome in schizophrenia. Schizophr Res 1992;6:257–65.
   PubMed Web of Science ®Google Scholar
• Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: A review. Schizophr Bull 2006;32 Suppl 1:S44–63.
   Web of Science ®Google Scholar
• Müller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004;37 Suppl 2:S141–7.
   Web of Science ®Google Scholar
• Taylor M, Chaudhry I, Cross M, Mcdonald E, Miller P, Pilowsky L, Strickland P. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol 2005;20:175–81.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, . Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287–96.
   PubMed Web of Science ®Google Scholar
• Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32, doi: 10.1186/1471 - 244X-8 - 32.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO, . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209–23.
   PubMed Web of Science ®Google Scholar
• Weiden PJ. Understanding and addressing adherence issues in schizophrenia: From theory to practice. J Clin Psychiatry 2007;68 Suppl 14:14–9.
   Web of Science ®Google Scholar
• Liu-Seifert H, Osuntokun OO, Feldman PD. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia. Compr Psychiatry 2011, doi:10.1016/j.comppsych.2010.12.003.
   PubMed Web of Science ®Google Scholar
• Meier J, Becker T, Patel A, Robson D, Schene A, Kikkert M, . Effect of medication-related factors on adherence in people with schizophrenia: A European multi-centre study. Epidemiol Psychiatr Soc 2010;19:251–9.
   PubMedGoogle Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011, doi: 10.1016/j.schres.2010.11.020.
   Google Scholar
• Uçok A, Polat A, Cakir S, Genç A. One year outcome in first episode schizophrenia. Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 2006;256:37–43.
   PubMed Web of Science ®Google Scholar
• Malla AK, Norman RM, Manchanda R, Ahmed MR, Scholten D, Harricharan R, . One year outcome in first episode psychosis: Influence of DUP and other predictors. Schizophr Res 2002;54: 231–42.
   PubMed Web of Science ®Google Scholar
• Lenior ME, Dingemans PM, Schene AH, Linszen DH. Predictors of the early 5-year course of schizophrenia: A path analysis. Schizophr Bull 2005;31:781–91.
   PubMed Web of Science ®Google Scholar
• Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia: A meta-analysis. Schizophr Bull 2001;27:73–92.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109–13.
   PubMed Web of Science ®Google Scholar
• Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76 - 338). Rockville, MD: National Institute of Mental Health. P. 218–22.
   Google Scholar
• Chabungbam G, Avasthi A, Sharan P. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin Neurosci 2007;61:587–93.
   PubMed Web of Science ®Google Scholar
• Hirsch S, Bowen J, Emami J, Cramer P, Jolley A, Haw C, Dickinson M. A one year prospective study of the effect of life events and medication in the aetiology of schizophrenic relapse. Br J Psychiatry 1996;168:49–56.
   PubMed Web of Science ®Google Scholar
• Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: The influence of clinical variables, relatives’ knowledge and expressed emotion. Psychol Med 2003;33:91–6.
   PubMed Web of Science ®Google Scholar
• Montero I, Gómez-Beneyto M, Ruiz I, Puche E, Adam A. The influence of family expressed emotion on the course of schizophrenia in a sample of Spanish patients. A two-year follow-up study. Br J Psychiatry 1992;161:217–22.
   PubMed Web of Science ®Google Scholar
• Marom S, Munitz H, Jones PB, Weizman A, Hermesh H. Expressed emotion: Relevance to rehospitalization in schizophrenia over 7 years. Schizophr Bull 2005;31:751–8.
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Faries De, Zhu B, Ernst Fr, Swartz Ms, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453–60.
   PubMed Web of Science ®Google Scholar
• Byerly MJ, , Nakonezny PaLescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30: 437–52.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Wirshing DA, Bhushan P, Pierre JM, Resnick SA, Wirshing WC. Lack of insight in schizophrenia: Impact on treatment adherence. CNS Drugs 2007;21:129–41.
   PubMed Web of Science ®Google Scholar
• Davies LM, Drummond MF. Economics and schizophrenia: The real cost. Br J Psychiatry 1994;25 Suppl:18–21.
   Google Scholar
• Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: A 12- and 24-month follow-up from the e-STAR Database in Spain. Appl Health Econ Health Policy 2008;6:41–53.
   PubMedGoogle Scholar
• Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209–22.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij De Weg H, Eriksson L, . Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501–9.
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. CNS Drugs 2009;23:649–59.
   PubMed Web of Science ®Google Scholar